Cost-effectiveness of psychotropic polypharmacy in routine schizophrenia care. Results of the ELAN prospective observational trial-Reference-Cited by-同舟云学术

Cost-effectiveness of psychotropic polypharmacy in routine schizophrenia care. Results of the ELAN prospective observational trial

Published:2018-12 Issue: Volume:30 Page:47-55
ISSN:0941-9500
Container-title:Neurology, Psychiatry and Brain Research
language:en
Short-container-title:Neurology, Psychiatry and Brain Research

Author:

Kilian Reinhold,Frasch Karel,Steinert Tilman,Schepp Wiltrud,Weiser Prisca,Jaeger Susanne,Pfiffner Carmen,Eschweiler Gerhard W.,Messer Thomas,Croissant Daniela,Längle Gerhard,Becker Thomas

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Neurology,General Neuroscience

Reference67 articles.

1. Utilization and costs of antipsychotic agents: A Canadian population-based study, 1996–2006;Alessi-Severini;Psychiatric Services,2008

2. Diagnostic and statistical manual of mental disorders (Fourth edition, text revision);American Psychiatric Association,2000

3. Antipsychotic use and expenditure in the United States;Aparasu;Psychiatric Services,2006

4. An introduction to propensity score methods for reducing the effects of confounding in observational studies;Austin;Multivariate Behavioral Research,2011

5. The use of the propensity score for estimating treatment effects: Administrative versus clinical data;Austin;Statistics in Medicine,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and cost-effectiveness of a web-based routine assessment with integrated recommendations for action for depression and anxiety (RehaCAT+): protocol for a cluster randomised controlled trial for patients with elevated depressive symptoms in rehabilitation facilities;BMJ Open;2022-06

2. Acknowledging Patient Heterogeneity in Economic Evaluations in Schizophrenia: A Systematic Review;Value in Health;2022-01

3. Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-02-23